Highlights Valerio Therapeutics

Equities

ALVIO

FR0010095596

Market Closed - Euronext Paris Other stock markets 11:23:35 2024-05-03 am EDT			5-day change	1st Jan Change
0.1088 ^EUR	+1.49%		-1.09%	-34.06%

Apr. 30	Valerio Therapeutics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Valerio Therapeutics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Valerio Therapeutics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 30	CI
Valerio Therapeutics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Onxeo SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-28	CI
Onxeo SA Provides Update on the Development Program For Drug Candidate AsiDNATM	23-01-25	CI
Onxeo SA Advances Its Second Lead Candidate Ox425 for the Treatment of Solid Tumors	22-11-30	CI
Onxeo SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-13	CI
Onxeo SA Announces the Enrollment of the First Patient in the Phase 1B/2 Clinical Study Conducted by the European Itcc Consortium and Sponsored by Institut Curie	22-09-01	CI
Onxeo SA Announces U.S. Food and Drug Administration Clears Initial IND Drug Candidate AsiDNA	22-06-30	CI
Onxeo SA Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-06	CI
Onxeo SA to Present New Preclinical Data Highlighting Asidna’s Ability to Fight Tumor Resistance and Protect from Anticancer Treatment Toxicity At Aacr Annual Meeting 2022	22-03-31	CI
Onxeo’s New Preclinical Data Confirm the Relevance of Combining AsiDNA™ With PARP Inhibitors in Treating Homologous Recombination Proficient Tumors	22-03-09	CI
Onxeo SA Announces New Preclinical Data Confirm the Ability of Asidna™ to Tackle the Drug-Tolerant Persister Cells and Prevent Tumor Resistance in Several Combination Treatments	21-12-08	CI
Onxeo Sa Reports Earnings Results for the Half Year Ended June 30, 2021	21-07-29	CI
Onxeo S.A. Receives Notice of Allowance for New Patent Broadening the Protection of AsiDNA™ in Combination with a PARP Inhibitor in the United States	21-06-09	CI
Onxeo S A : Creates Scientific Advisory Committee For Cancer Therapy Development	21-05-31	MT
Global markets live: Chevron, Toyota, Sony...	21-04-22
Onxeo to Present New Preclinical Data at AACR 2021	21-04-08	CI
Rights Issue: 1 new share @ 0.71 EUR for 6 existing shares	21-03-16	FA
Onxeo Enters Clinical Research Agreement with Institut Curie to Conduct a Phase 1b/2 Clinical Trial of AsiDN	21-02-04	CI
Onxeo S.A. Announces Completion of Patient Enrollment in DRIIV-1b Study	20-11-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Valerio Therapeutics

Equities

ALVIO

FR0010095596

Highlights

Filters